Linda D. Bradley

No ORCID on file · 5 papers in corpus · active 2000-2022

Study types

  • article 4
  • review 1

Condition tags

  • adenomyosis 2
  • endometriosis 1
article 2022
American journal of obstetrics and gynecology ·doi:10.1016/j.ajog.2022.01.021

BackgroundDespite an estimated 10% prevalence of endometriosis among reproductive-age women, surgical population-based data are limited.ObjectiveWe sought to investigate racial and ethnic disparities in surgical interventions and complicati…

article 2021
F&S reports ·doi:10.1016/j.xfre.2021.05.004

OBJECTIVE: To determine if coexisting adenomyosis limits the efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy in reducing heavy menstrual bleeding in women with uterine fibroids. DESIGN…

article 2020
·doi:10.1097/01.aog.0000663140.66314.38

INTRODUCTION: Evaluate the efficacy of elagolix with add-back therapy on menstrual blood loss (MBL) and safety in women with uterine fibroids (UF), heavy menstrual bleeding (HMB) and adenomyosis. METHODS: Pooled data from two investigationa…

article 2019
·doi:10.1016/j.fertnstert.2019.07.344
review 2000
Obstetrics and gynecology clinics of North America ·doi:10.1016/s0889-8545(00)80019-4

The introduction of SIS has been a significant advance in TVUS evaluation of the endometrial cavity in the 1990s. SIS provides an unparalleled, clear, enhanced view of the endomyometrial complex that cannot be obtained with TVUS alone. Foca…